Vera Therapeutics Makes Significant Strides in IgA Nephropathy Treatment with Positive Phase 3 Data for Atacicept and Strategic Inducement Grants BRISBANE, Calif., Nov. 6, 2025 Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing transformative treatments for patients with rare autoimmune diseases, has recently announced promising data from its ORIGIN Phase 3 trial of atacicept for the treatment of IgA nephropathy (IgAN). This breakthrough was highlighted in a featured late-breaking oral presentation during the opening plenary session of the American Society of Nephrology (ASN) Kidney Week 2025 and was simultaneously published in the prestigious New Englan...
In a strategic move to bolster its workforce and drive forward its mission of developing transformative therapies for patients with immunological diseases, Vera Therapeutics, Inc. (Nasdaq: VERA), a forward-thinking biopharmaceutical company, has announced the issuance of inducement grants to a cohort of new employees. This significant step is indicative of Vera s commitment to attracting top talent in the fiercely competitive biotech industry. Details of the Inducement Grants The inducement awards, granted on May 5, 2025, were approved by the Compensation Committee of Vera Therapeutics. These awards consist of nonqualified stock options for the purchase of 111,750 shares of Class A common stock, coupled with...
Vera Therapeutics, Inc. a late clinical-stage biotechnology company dedicated to developing transformative treatments for severe immunological disorders, has announced the completion of patient enrollment for the primary endpoint in its pivotal Phase 3 ORIGIN 3 trial of atacicept for IgA nephropathy (IgAN). This milestone marks a significant advancement in the development of atacicept, a promising therapeutic candidate. Enrollment of 200 participants in this initial cohort will yield data crucial for the 36-week urine protein-to-creatinine ratio (UPCR) primary efficacy endpoint, facilitating future regulatory approval processes. IgA nephropathy (IgAN), a chronic kidney disease characterized by the depositio...
Sources:
Vera Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Vera Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Vera Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
